Denmark· DK-28106676821
Opdualag
A nivolumab and relatlimab product containing nivolumab, relatlimab, registered in Denmark by Bristol-Myers Squibb Pharma EEIG. The same ATC class is registered in 13 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Nivolumab and relatlimab is registered in 13 of 19 countries.
Countries holding a registration under ATC L01FY02 (nivolumab and relatlimab), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 9 of them publish a price we can compare per daily dose
Nivolumab and relatlimab · ATC L01FY02
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- Nivolumab, Relatlimab
- Manufacturer
- Bristol-Myers Squibb Pharma EEIG
- Country
- Denmark (DK)
- ATC code
- L01FY02
- ATC class
- Nivolumab and relatlimab
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28106676821
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under L01FY02
Nivolumab and relatlimab, as other registers publish it.
- IcelandOpdualagBristol-Myers Squibb Pharma EEIG*
- NorwayOpdualagBristol-Myers Squibb Pharma EEIG (1)
- FinlandOpdualagBristol-Myers Squibb Pharma EEIG
- PolandOpdualagBristol-Myers Squibb Pharma EEIG
- CzechiaOPDUALAGBristol-Myers Squibb Pharma EEIG, Dublin
- United StatesOPDUALAGE.R. Squibb & Sons, L.L.C.
- CanadaOPDUALAGBRISTOL-MYERS SQUIBB CANADA
- SwitzerlandOpdualag (80 mg Relatlimab / 240 mg Nivolumab pro 20 ml), Konzentrat zur Herstellung einer InfusionslösungBristol-Myers Squibb SA
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b2e8b773-ad09-4033-8c4e-e5c325fd2288 GET /v1/drugs/b2e8b773-ad09-4033-8c4e-e5c325fd2288?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "koncentrat til infusionsvæske, opløsning",
"source": "dkma",
"strength": "240+80 mg",
"auth_role": "MOD",
"dk_drugid": "28106676821",
"substance": "Nivolumab, Relatlimab",
"auth_procedure": "Central",
"in_medicinpriser": true,
"registration_date_serial": "44819"
}See everything about nivolumab and relatlimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.